MeSH term
Frequency | Condition_Probility | Humans | 184 | 0.0 |
United States | 3 | 0.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Kinetics | 8 | 0.0 |
Research Support, Non-U.S. Gov't | 93 | 0.0 |
Immunohistochemistry | 10 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Male | 118 | 0.0 |
Prostatic Neoplasms/*diagnosis | 7 | 14.0 |
Reproducibility of Results | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 19 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Tissue Kallikreins/*biosynthesis | 2 | 100.0 |
Animals | 31 | 0.0 |
Base Sequence | 19 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Evolution, Molecular | 3 | 0.0 |
Infant | 4 | 0.0 |
Molecular Sequence Data | 33 | 0.0 |
*Mutation | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 38 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Aged | 34 | 0.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Kallikreins/*biosynthesis | 3 | 50.0 |
Middle Aged | 37 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Prognosis | 8 | 0.0 |
Tumor Markers, Biological/*analysis | 6 | 0.0 |
Cells, Cultured | 7 | 0.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Reference Values | 6 | 0.0 |
Cell Division | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Fluoroimmunoassay | 5 | 11.0 |
Female | 35 | 0.0 |
Mice | 15 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Pregnancy | 6 | 0.0 |
Rabbits | 4 | 0.0 |
Semen/enzymology | 2 | 18.0 |
Gene Expression | 5 | 0.0 |
Organ Specificity | 5 | 0.0 |
Tumor Cells, Cultured | 24 | 0.0 |
Comparative Study | 31 | 0.0 |
DNA Primers | 5 | 0.0 |
Blotting, Western | 17 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Disease Progression | 4 | 0.0 |
Prostate/metabolism | 4 | 5.0 |
Protein Binding | 8 | 0.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
Time Factors | 9 | 0.0 |
Case-Control Studies | 3 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Neoplasm Staging | 12 | 0.0 |
RNA, Messenger/*blood | 3 | 8.0 |
Sensitivity and Specificity | 23 | 0.0 |
Prostate-Specific Antigen/*blood | 18 | 20.0 |
Prostatic Hyperplasia/blood/diagnosis | 2 | 66.0 |
Prostatic Neoplasms/*blood/*diagnosis | 6 | 100.0 |
Tissue Kallikreins/*blood | 22 | 91.0 |
Area Under Curve | 4 | 0.0 |
Cohort Studies | 3 | 0.0 |
Prostate-Specific Antigen/blood | 8 | 9.0 |
Prostatic Neoplasms/*blood/*pathology | 3 | 50.0 |
ROC Curve | 2 | 1.0 |
Cell Division/drug effects | 2 | 0.0 |
Testosterone Congeners/pharmacology | 2 | 11.0 |
Transfection | 9 | 0.0 |
Cell Line | 9 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Models, Statistical | 2 | 1.0 |
Plasmids/metabolism | 2 | 0.0 |
Prostate/*metabolism | 4 | 5.0 |
Prostatic Neoplasms/*metabolism | 3 | 2.0 |
Keratin/metabolism | 2 | 1.0 |
Rats | 5 | 0.0 |
Hydrolysis | 3 | 0.0 |
Prostate/*enzymology | 5 | 4.0 |
*Antibodies, Monoclonal | 3 | 1.0 |
Cross Reactions | 14 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 11 | 0.0 |
Prostatic Diseases/blood | 2 | 66.0 |
Binding Sites | 4 | 0.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
Prostatic Neoplasms/metabolism | 3 | 5.0 |
Aged, 80 and over | 14 | 0.0 |
Predictive Value of Tests | 9 | 0.0 |
Prostatectomy | 5 | 6.0 |
Adult | 19 | 0.0 |
Prostate-Specific Antigen/*urine | 2 | 100.0 |
Tissue Kallikreins/*urine | 2 | 100.0 |
Enhancer Elements (Genetics) | 3 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Transcription, Genetic | 9 | 0.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Blotting, Northern | 4 | 0.0 |
Amino Acid Sequence | 22 | 0.0 |
Amniotic Fluid/chemistry | 2 | 5.0 |
Body Fluids/*chemistry | 3 | 10.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
In Vitro | 2 | 0.0 |
Milk, Human/chemistry | 2 | 13.0 |
Semen/chemistry | 6 | 42.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Tumor Markers, Biological/*blood | 7 | 1.0 |
Introns | 2 | 0.0 |
Multivariate Analysis | 6 | 0.0 |
Prostatic Neoplasms/blood/*diagnosis | 4 | 40.0 |
*Reverse Transcriptase Polymerase Chain Reaction | 2 | 3.0 |
Sequence Analysis, DNA | 3 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Prostate-Specific Antigen/metabolism | 4 | 11.0 |
alpha 1-Antichymotrypsin/chemistry | 2 | 100.0 |
Prostate-Specific Antigen/*metabolism | 6 | 28.0 |
Diagnosis, Differential | 9 | 0.0 |
Prostate-Specific Antigen/*genetics | 6 | 30.0 |
Tissue Kallikreins/*genetics | 6 | 50.0 |
English Abstract | 5 | 0.0 |
Antibodies, Monoclonal | 8 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Prostate/enzymology | 2 | 3.0 |
Antibody Specificity | 7 | 0.0 |
Prostate-Specific Antigen/blood/metabolism | 2 | 66.0 |
Prostate-Specific Antigen/analysis | 3 | 6.0 |
Tissue Kallikreins/analysis | 2 | 100.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Adolescent | 4 | 0.0 |
Prostate-Specific Antigen/*blood/*urine | 2 | 66.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Steroids/*pharmacology | 2 | 10.0 |
Prostatic Neoplasms/*blood | 5 | 19.0 |
Biopsy | 2 | 0.0 |
Prostate/pathology | 3 | 13.0 |
Risk Factors | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Kallikreins/*genetics | 7 | 28.0 |
*Multigene Family | 2 | 0.0 |
Child | 3 | 0.0 |
Epitopes | 5 | 0.0 |
Hamsters | 6 | 0.0 |
Prostate-Specific Antigen/*immunology | 7 | 63.0 |
Recombinant Proteins/immunology | 6 | 1.0 |
Tissue Kallikreins/*immunology | 2 | 100.0 |
Antibodies, Monoclonal/immunology | 5 | 0.0 |
Antibodies, Monoclonal/*immunology | 4 | 0.0 |
Immunoassay | 9 | 3.0 |
Epitopes/immunology | 2 | 0.0 |
Models, Molecular | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Terminology | 2 | 1.0 |
Prostatic Neoplasms/*diagnosis/pathology | 2 | 13.0 |
DNA Primers/genetics | 2 | 0.0 |
Enzyme Activation | 6 | 0.0 |
Hexokinase/*genetics | 4 | 26.0 |
Isoenzymes/genetics | 2 | 0.0 |
Prostatic Hyperplasia/*blood/diagnosis | 2 | 100.0 |
Age Factors | 4 | 0.0 |
Prostate-Specific Antigen/*analysis | 3 | 13.0 |
Kallikreins/*analysis | 6 | 66.0 |
Tissue Kallikreins | 38 | 82.0 |
Kallikreins/*metabolism | 8 | 50.0 |
Serpins/*metabolism | 2 | 12.0 |
Tumor Markers, Biological | 4 | 0.0 |
Kallikreins/physiology | 2 | 50.0 |
Prostatic Neoplasms/*pathology | 2 | 1.0 |
Cell Line, Transformed | 3 | 0.0 |
Gene Expression/drug effects | 3 | 0.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Conserved Sequence | 2 | 0.0 |
*Phylogeny | 2 | 1.0 |
Kidney Tubules, Proximal/cytology/*metabolism | 2 | 18.0 |
Transforming Growth Factor beta/*pharmacology | 2 | 0.0 |
Gonadal Steroid Hormones/metabolism | 2 | 10.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Peptides/metabolism | 2 | 0.0 |
*Seminal Vesicle Secretory Proteins | 2 | 33.0 |
Serpins/metabolism | 2 | 12.0 |
Chromatography, Gel | 3 | 0.0 |
Phylogeny | 2 | 0.0 |
Prostatic Neoplasms/blood/surgery | 2 | 66.0 |
alpha 1-Antichymotrypsin/metabolism | 2 | 22.0 |
Kallikreins/*analysis/immunology | 4 | 100.0 |
Prostate-Specific Antigen/*blood/immunology | 2 | 100.0 |
Tumor Markers, Biological/blood | 3 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Bradykinin/metabolism | 2 | 14.0 |
Semen/*enzymology | 2 | 10.0 |
Kallikreins/analysis/*biosynthesis | 2 | 50.0 |
Lymphatic Metastasis | 2 | 0.0 |
Tumor Markers, Biological/analysis/*biosynthesis | 2 | 14.0 |
Prostatic Neoplasms/enzymology | 2 | 10.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Kallikreins/*immunology | 3 | 100.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Kallikreins/analysis | 2 | 28.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Kallikreins/genetics | 2 | 28.0 |
Prostate/*metabolism/pathology | 2 | 15.0 |
Kallikreins/*biosynthesis/genetics/secretion | 2 | 100.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Prostatic Hyperplasia/blood | 3 | 13.0 |
alpha 1-Antichymotrypsin/blood | 2 | 22.0 |
Semen/*metabolism | 3 | 16.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Prostate/*chemistry | 3 | 30.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Prostatic Hyperplasia/blood/*diagnosis | 2 | 66.0 |
Epithelial Cells/*metabolism | 2 | 1.0 |
Prostatic Hyperplasia/diagnosis | 2 | 9.0 |
Catalysis | 2 | 0.0 |
Prostate/*physiology | 2 | 20.0 |
Kallikreins/genetics/isolation & purification/*metabolism | 2 | 100.0 |
Prostatic Neoplasms/diagnosis | 2 | 33.0 |
Substrate Specificity | 3 | 0.0 |
*Neoplasm Circulating Cells | 2 | 5.0 |
Escherichia coli | 2 | 0.0 |
Recombinant Proteins | 4 | 0.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Alleles | 2 | 0.0 |
Diabetes Mellitus, Type 2/*genetics | 2 | 1.0 |
Linkage (Genetics) | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Molecular Weight | 3 | 0.0 |
Prostatic Hyperplasia/blood/*pathology | 2 | 66.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Isoenzymes/*genetics | 2 | 0.0 |
*Mass Screening | 2 | 3.0 |
Tissue Kallikreins/*analysis | 2 | 100.0 |
Molecular Structure | 2 | 0.0 |
L Cells (Cell Line) | 2 | 0.0 |
Myocardium/*metabolism | 2 | 0.0 |
Biopsy, Needle | 2 | 0.0 |
Nipples | 2 | 40.0 |
Postmenopause | 2 | 1.0 |
Premenopause | 2 | 2.0 |
Tissue Kallikreins/metabolism | 2 | 40.0 |
*Cloning, Molecular | 2 | 0.0 |
Altruism | 2 | 6.0 |
*Blood Donors/supply & distribution | 2 | 10.0 |
Blood Transfusion/*adverse effects/standards | 2 | 10.0 |
Developing Countries | 2 | 2.0 |
HIV Infections/*transmission | 2 | 3.0 |
Infant, Newborn | 2 | 0.0 |
Peru | 2 | 4.0 |
Reward | 2 | 5.0 |
Safety | 2 | 1.0 |
Socioeconomic Factors | 2 | 1.0 |
Salvage Therapy | 2 | 2.0 |
Follow-Up Studies | 2 | 0.0 |
Tissue Kallikreins/*blood/genetics | 2 | 100.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
Hexokinase/*blood | 2 | 40.0 |
Biological Markers | 2 | 0.0 |
